Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.

Official Title

AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Details

To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.

Keywords

Primary Biliary Cholangitis, Primary Biliary Cholangitis (PBC), PBC, Cholangitis, Biliary Liver Cirrhosis, Seladelpar

Eligibility

Locations

  • Connie Frank Transplant Center at UCSF accepting new patients
    San Francisco California 94143 United States
  • California Pacific Medical Center - Sutter Pacific Medical Foundation accepting new patients
    San Francisco California 94109 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Gilead Sciences
Links
Gilead Clinical Trials Website
ID
NCT06051617
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 318 study participants
Last Updated